Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 12, 2006, Pages 1149-1156

  Rousseau, Audrey ^a,b   Nutt, Catherine L ^a   Betensky, Rebecca A ^c   Iafrate, A John ^a   Han, Moonjoo ^a   Ligon, Keith L ^d   Rowitch, David H ^d   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

ApoE; ASCL1; Astrocytoma; Immunohistochemistry; NKX2 2; Oligodendroglioma; YKL 40

Indexed keywords

APOLIPOPROTEIN E; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN; HOMEODOMAIN PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN ASCL1; PROTEIN YKL 40; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR SOX10;

ARTICLE; ASTROCYTE; ASTROCYTOMA; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

EID: 33845394445     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000248543.90304.2b     Document Type: Article

References (51)

1. Reifenberger G, Kros JM, Burger PC, et al. Oligoastrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours. Lyon: IARC, 2000:65-67
2. Sung CC, Collins R, Li J, et al. Glycolipids and myelin proteins in human oligodendrogliomas. Glycoconj J 1996;13:433-43
3. Nakagawa Y, Perentes E, Rubinstein LJ. Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta Neuropathol (Berl) 1986;72:15-22
4. Lu QR, Yuk D, Alberta JA. Sonic hedgehog-regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 2000;25:317-29
5. Zhou Q, Wang S, Anderson DJ. Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 2000;25:331-43
6. Wegner M. Expression of transcription factors during oligodendroglial development. Microsc Res Tech 2001;52:746-52
7. Lu QR, Park JK, Noll E, et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 2001;98:10851-56
8. Marie Y, Sanson M, Mokhtari K, et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001;358:298-300
9. Hoang-Xuan K, Aguirre-Cruz L, Mokhtari K, et al. OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol 2002;28:89-94
10. Ohnishi A, Sawa H, Tsuda M, et al. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. J Neuropathol Exp Neurol 2003;62:1052-59
11. Ligon KL, Alberta JA, Kho AT, et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004;63:499-509
12. Reifenberger G, Kros JM, Burger PC, et al. Anaplastic oligoastrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours. Lyon: IARC, 2000:68-69
13. Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC, 2000
14. Clancy R. Nitric oxide alters chondrocyte function by disrupting cytoskeletal signalling complexes. Osteoarthritis Cartilage 1999;7:399-400
15. De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926-31
16. Nishikawa KC, Millis AJT. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79-87
17. Malinda KM, Ponce L, Kleinman HK, et al. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-73
18. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202
19. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003;80:15-21
20. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003;9:4423-34
21. Cintin C, Johansen JS, Christensen IJ, et al. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002;95:267-74
22. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-39
23. Markert JM, Fuller CM, Gillepsie GY, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001;5:21-33
24. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-68
25. Shostak K, Labunskyy V, Dmitrenko V, et al. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett 2003;198:203-10
26. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastomas. Cancer Res 2005;65:1678-86
27. Nutt CL, Betensky RA, Brower MA, et al. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 2005;11:2258-64
28. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-607
29. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005;11:3326-34
30. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:147-48
31. Elshourbagy NA, Liao WS, Mahley RW, et al. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A 1985;82:203-207
32. Boyles JK, Pitas RE, Wilson E, et al. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985;76:1501-13
33. Pitas RE, Boyles JK, Lee SH, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochem Biophys Acta 1987;917:148-61
34. Murakami M, Ushio Y, Morino Y, et al. Immunohistochemical localization of apolipoprotein E in human glial neoplasms. J Clin Invest 1988;82:177-88
35. Bachoo RM, Ryung SK, Ligon KL, et al. Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A 2004;101:8384-89
36. Gee JR, Keller JN. Astrocytes: Regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol 2005;37:1145-50
37. Poirier J, Hess M, May PC, et al. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res Mol Brain Res 1991;11:97-106
38. Nicoll JA, Zunarelli E, Rampling R, et al. Involvement of apolipoprotein E in glioblastoma: Immunohistochemistry and clinical outcome. Neuroreport 2003;14:1923-26
39. Parras CM, Galli R, Britz O, et al. Mash1 specifies neurons and oligodendrocytes in the postnatal brain. EMBO J 2004;23:4495-505
40. Zhou Q, Choi G, Anderson DJ. The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron 2001;31:791-807
41. Qi Y, Cai J, Wu Y, et al. Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development 2001;128:2723-33
42. Sun T, Dong H, Wu L, et al. Cross-repressive interaction of the Olig2 and Nkx2.2 transcription factors in developing neural tube associated with formation of a specific physical complex. J Neurosci 2003;23:9547-56
43. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002;3:167-70
44. Kuhlbrodt K, Herbarth B, Sock E, et al. Sox10, a novel transcriptional modulator in glial cells. J Neurosci 1998;18:237-50
45. Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001;15:66-78
46. Stolt CC, Rehberg S, Ader M, et al. Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes Dev 2002;16:165-70
47. Bannykh SI, Stolt CC, Kim J, et al. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neuroncol 2006;76:115-27
48. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003;100:15178-83
49. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-77
50. Dai C, Lyustikman Y, Shih A, et al. The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 2005;7:397-406
51. Hu X, Pandolfi PP, Li Y, et al. mTOR promotes survival and astrocytic characteristics induced by Pten/Akt signaling in glioblastoma. Neoplasia 2005;7:356-68